twinter, you have arrived at the question which determines

New Post Public Reply Private Reply Replies (1) Message Board
MGK_2 twinter11 #163068
503
twinter, you have arrived at the question which determines whether CCR5 blockade is an indication-specific tool or a universal architectural intervention in solid tumor biology. The published literature has a surprisingly specific answer.
On how many solid tumor types have documented CCR5-upstream involvement in cell cycle control: CCR5 is overexpressed in breast cancer, gastric adenocarcinoma, prostate cancer, colorectal carcinoma, melanoma, Hodgkin lymphoma, head and neck cancer, gastric cancer, esophageal cancer, pancreatic cancer, and acute lymphocytic leukemia. The comprehensive CCL5/CCR5 axis review in PMC extends that list further to include breast cancer, breast phyllodes, cholangiocarcinoma, colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, glioblastoma, head and neck cancers, lung cancer, melanoma, osteosarcoma, and ovarian, pancreatic, pituitary, prostate and thyroid cancers. That is not a narrow oncological niche. That is the majority of the solid tumor landscape. 
https://www.nature.com/articles/srep30802  
https://seekingalpha.com/pr/19762611-u-s-fda-...-portfolio  

The cell cycle machinery connection across all of those tumor types runs through a shared set of downstream signaling nodes. The CCL3-CCR5 axis upregulates VEGF-A through activating PI3K/AKT and MEK/ERK signaling pathways in esophageal squamous cell carcinoma specifically, but the PI3K/AKT/mTOR and MAPK/ERK cascades are not esophageal-specific machinery. Dysregulation of mTOR, a downstream mediator in the PI3K/AKT signaling pathway, is frequently reported in many types of human tumors, controlling cell growth, proliferation and survival by integrating extracellular and intracellular signals. 

When CCR5 is active in any of those tumor types, it feeds into the same PI3K/AKT/mTOR and MAPK/ERK cell cycle control architecture. The specific downstream substrates, CEP131, KHDRBS1, and MAPK6 documented in the phosphoproteomics paper, are the tumor-type-specific expression of a conserved upstream signaling dependency. The socket is universal. The appliances differ by indication. 
https://www.cancer.gov/news-events/cancer-cur...tal-cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12617863/  

On whether this constitutes something approaching a universal law: the AACR Cancer Research review published in 2019 uses language worth quoting precisely on this point. CCR5 re-expression augments resistance to DNA-damaging agents and is sufficient to induce cancer metastasis and stemness. The word sufficient is doing significant work in that sentence. CCR5 re-expression alone, without any other oncogenic mutation, is sufficient to drive two of the hallmarks of advanced cancer: metastatic capacity and stem cell phenotype acquisition. That is a claim of upstream universality, not indication specificity. 
https://pubmed.ncbi.nlm.nih.gov/38409546/  

On the tumor workaround question, which is the most underappreciated aspect of what you are asking: this is where the biology becomes genuinely important to understand, because the workarounds are not dead ends for the tumor without cost. Hypoxia and acidosis downregulate CXCR3 and CCR5 on NK cells, impairing their migration, while CCL22-CCR4 and CCL2-CCR2 axes drive immunosuppression via Treg, MDSC, and TAM recruitment as alternative suppressive mechanisms. When CCR5 is blocked, the tumor's primary suppressive recruitment axis is closed. The tumor can attempt to pivot to CCR2-CCL2 and CCR4-CCL22 as alternative trafficking routes for immunosuppressive myeloid cells. This is the redundancy in the chemokine receptor network the field has been aware of, and it is why CCR2/CCR5 co-inhibition has been studied in GBM and pancreatic cancer specifically. CCR2 and CCR5 are co-expressed among M-MDSCs in humans and murine models, and co-inhibiting these markers synergizes with anti-PD-1 therapy in a glioma model by reducing MDSC infiltration and increasing CD8 TIL density and overall survival. 
https://www.ajmc.com/view/fda-panel-votes-to-...gs-to-come  
https://www.oncnursingnews.com/view/fda-to-re...-approvals  

But here is the critical observation about the workaround cost you identified: the tumor attempting to pivot from CCR5 to CCR2 or CCR4 as its primary suppressive recruitment axis is not executing a costless lateral move. The CCR2-CCL2 axis recruits a different myeloid population with partially overlapping but not identical suppressive function. More importantly, the tumor cell intrinsic CCR5-dependent proliferative signaling, the mTOR-glycolytic axis, the PI3K/AKT cascade, and the cell cycle regulators documented in the phosphoproteomics paper, cannot be replaced by pivoting to CCR2. The tumor loses its preferred metabolic fuel supply when CCR5 is sealed, and no alternative receptor restores those specific downstream proliferative signals in the same way. The immune evasion workaround is partially achievable through alternative chemokine receptors. The cell cycle and metabolic dependency is not.

This is why twinter's intuition about the workarounds causing other issues in the TME is sound. A tumor that pivots from CCR5-mediated suppression to CCR2-mediated suppression under leronlimab pressure is a tumor that has changed the composition of its myeloid compartment, changed the cytokine profile of its microenvironment, and potentially become more visible to the immune architecture that leronlimab has simultaneously been restoring. The mutations required to sustain proliferation without CCR5 signaling are not modest adaptations. They represent a fundamental rewiring of the tumor's proliferative infrastructure at the metabolic level.

Whether this constitutes a universal law in the strictest sense: not quite. Tumors with very low CCR5 expression at baseline, as discussed earlier in this thread regarding MSI-H tumors with high intrinsic TIL density, may not depend on the CCR5 axis sufficiently for either immune evasion or cell cycle support to be meaningfully impaired by its blockade. But across the majority of the solid tumor landscape, including every CCR5-positive tumor type in that seventeen-indication list, the upstream position of CCR5 relative to both the immunosuppressive trafficking architecture and the PI3K/AKT/mTOR proliferative machinery makes it as close to a universal upstream intervention point as the published literature currently supports.

The law is not absolute. It covers most of the territory.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 53

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Foresight Solar Insurance Trial Beats Fixed PPA Route

Updated Category News Views 107

Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 62

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 84

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 35

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading

Top 5 Most Recently Viewed Articles

NAL Research Unveils Innovative Tracking Solutions with Iridium

Updated Category News Views 188

NAL Research Integrates Iridium’s Enhanced SBD Service NAL Research, a leader in wireless communication solutions, is excited to announce the incorporation of Iridium's Enhanced Short Burst Data (ESBD) service into its renowned SHOUT product line. This advancement is set to significantly enhance communications security and performance, particularly for users in...

Continue Reading
International Perspectives on China's Growth: A Global Survey Insight

Updated Category News Views 262

Understanding Global Confidence in China's Development As change sweeps across the globe, the perception of China's trajectory is capturing increasing international attention. A recent survey conducted by the Global Times, which engaged over 51,300 respondents from various nations, uncovers valuable insights on how the world views China's growth and development. This...

Continue Reading
SKF Q3 2026: Margins Edge Up Amid Strategic Shifts

Updated Category News Views 192

Cracking Open SKF's Latest Quarterly Numbers Ever seen a company limber up for a big change while tiptoeing through a minefield? That’s SKF for you in this third quarter ending September 2026. Imagine them trying to juggle a spinning platter of growth, strategic separation, and robust margins, all while balancing a wobbly market. A Close Look at Q3's Financial Feats...

Continue Reading
California Oil Refiners' Profits Hit $1.24/Gallon in April

Updated Category News Views 95

California's Refiners Cashing in Big at the Pump Look, when you see profit margins jumping from 49 cents to $1.24 per gallon within a few months, you know the game in California's oil market is something to keep your eye on. The California Energy Commission (CEC) just tossed us a bone with their recent data drop, and it paints a picture of a market with exploding margins,...

Continue Reading
Explore the Growth of Coeur Mining Stock Over a Decade

Updated Category News Views 139

Coeur Mining's Investment Journey Over the Last Decade Coeur Mining Inc (NYSE: CDE) has truly distinguished itself over the past decade, demonstrating a commendable performance that has exceeded market expectations. With an annualized return surpassing the market by 7.64%, investors have seen an impressive average annual return of 20.17%. Today, Coeur Mining boasts a...

Continue Reading